Stock listing
NYSE:BHVN Biohaven Pharmaceutical Holding Co Ltd Stock
Follow Biohaven Pharmaceutical Holding Co Ltd into a list and get an email when it puts out news.
Last close · NYSE:BHVN
$151.80 USD
Close on Oct 3, 2022 · No longer trades
- Lowest – highest close
- $17.50 – $152.20 USDSince May 4, 2017 · lowest May 4, 2017 · highest Sep 27, 2022
Delisted NYSE:BHVN no longer trades. Its last trading date is unknown. Company history and updates stay available on this page.
- Ticker
- NYSE:BHVN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NYSE
- Currency
- USD
Biohaven Pharmaceutical Holding Co Ltd on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- Decks
- 12 decks · latest Sep 27, 2021
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Oct 29, 2026 · After close | −6.5% |
| Quarter to Jun 30, 2026 | Aug 10, 2026 · After close | −0.3% |
| Quarter to Mar 31, 2026 | May 4, 2026 · After close | −4.2% |
| Quarter to Dec 31, 2025 | Mar 19, 2026 | −1.8% |
| Quarter to Sep 30, 2025 | Nov 10, 2025 · Before open | −5.7% |
| Quarter to Jun 30, 2025 | Aug 11, 2025 · Before open | −9.0% |
| Quarter to Mar 31, 2025 | May 12, 2025 · After close | −5.1% |
| Quarter to Dec 31, 2024 | Mar 3, 2025 | −15.6% |
| Quarter to Sep 30, 2024 | Nov 12, 2024 · After close | −2.6% |
| Quarter to Jun 30, 2024 | Aug 8, 2024 · After close | +6.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2024 | May 9, 2024 · After close | −13.7% |
| Quarter to Dec 31, 2023 | Feb 29, 2024 · After close | +2.9% |
| Quarter to Sep 30, 2023 | Nov 14, 2023 · After close | −2.5% |
| Quarter to Jun 30, 2023 | Jul 31, 2023 · Before open | +4.4% |
| Quarter to Mar 31, 2023 | May 12, 2023 · After close | +6.9% |
| Quarter to Dec 31, 2022 | Mar 23, 2023 · After close | +6.6% |
| Quarter to Sep 30, 2022 | Nov 9, 2022 · Before open | −5.3% |
| Quarter to Jun 30, 2022 | Aug 5, 2022 · Before open | |
| Quarter to Mar 31, 2022 | May 10, 2022 · Before open | |
| Quarter to Dec 31, 2021 | Feb 25, 2022 · Before open |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2021) | Investor deck | 89 slides | Sep 27, 2021 |
| Leerink Fireside Chat June 2021 | Conference | 23 slides | Jun 29, 2021 |
| Investor Presentation (June 2020) | Investor deck | 76 slides | Jun 2, 2020 |
| Technical Presentation (March 2020) | Technical | 8 slides | Mar 31, 2020 |
| Corporate Update (February 2020) | Corporate update | 17 slides | Feb 28, 2020 |
| Investor Presentation (January 2020) | Investor deck | 71 slides | Jan 13, 2020 |
| Investor Presentation (October 2019) | Investor deck | 67 slides | Oct 3, 2019 |
| Wells Fargo Healthcare Conference 2019 | Conference | 64 slides | Sep 4, 2019 |
| Technical Presentation (May 2019) | Technical | 35 slides | May 8, 2019 |
| Corporate Update (December 2018) | Corporate update | 15 slides | Dec 3, 2018 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (March 2018) | Technical | 19 slides | Mar 26, 2018 |
| Investor Presentation (October 2017) | Investor deck | 40 slides | Oct 18, 2017 |
Cap table
Built by 6ix from Biohaven Pharmaceutical Holding Co Ltd’s releases
- Common shares
- 151,043,781
- Fully diluted
- 151,043,781
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 151,043,781 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 151,043,781 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Vlad Coric Other companies: Veradermics, Incorporated (Board Member · Since at least Feb 3, 2026); Royalty Pharma plc (Director · Since at least Apr 7, 2025); Biohaven Ltd. (Chairman & Chief Executive Officer · Since at least Sep 22, 2022); Revance Therapeutics, Inc. (Director · Mar 1, 2023 – Feb 4, 2025 · Past); Akili Inc (Director · Jun 29, 2021 – Jun 29, 2021 · Past) | Chief Executive Officer, Director · May 3, 2017 – Oct 3, 2022 · Past |
| Albert Cha Other companies: Ascendis Pharma A/S (Chairman · Since at least Mar 18, 2026); KalVista Pharmaceuticals, Inc. (Director · Mar 23, 2017 – Sep 26, 2023 · Past); Aclaris Therapeutics, Inc. (Director · Oct 6, 2015 – Jun 29, 2016 · Past); Sierra Oncology Inc (Director · Jul 15, 2015 – Jul 21, 2015 · Past) | Director · May 3, 2017 – May 1, 2018 · Past |
| Julia P. Gregory Other companies: Biohaven Ltd. (Director · Since at least Sep 28, 2022); Nurix Therapeutics, Inc. (Chair · Since at least Jul 23, 2020); Lexicon Pharmaceuticals, Inc. (EVP and CFO · Feb 7, 2008 – Feb 7, 2008 · Past) | Director · Aug 2, 2017 – Oct 3, 2022 · Past |
| John W. Childs Other companies: Veradermics, Incorporated (Chairman · Since at least Feb 3, 2026); Biohaven Ltd. (Director · Since at least Sep 28, 2022) | Director · Mar 22, 2019 – Oct 3, 2022 · Past |
| Declan Doogan Other companies: Tenax Therapeutics, Inc. (Director · Since at least Feb 25, 2021) | Director · May 5, 2021 – Feb 11, 2022 · Past |
| Irina A. Antonijevic Other companies: Biohaven Ltd. (Director · Since at least Sep 28, 2022) | Director · May 1, 2022 – Oct 3, 2022 · Past |
| John Tilton Other companies: Biohaven Ltd. (Chief Commercial Officer, Rare Disease · Since at least Nov 4, 2026) | Chief Commercial Officer · May 3, 2017 – Oct 3, 2022 · Past |
| Kimberly Gentile Other companies: Biohaven Ltd. (Senior Vice President, Clinical Operations · Since at least Sep 28, 2022) | SVP, Clinical Operations · May 3, 2017 – Oct 3, 2022 · Past |
| Matthew Buten Other companies: Biohaven Ltd. (Chief Financial Officer · Since at least Sep 22, 2022) | Chief Financial Officer · Dec 8, 2021 – Oct 3, 2022 · Past |
| Robert Repella Other companies: Vanda Pharmaceuticals Inc. (SVP & Chief Commercial Officer · Oct 24, 2011 – Nov 19, 2013 · Past) | Director · Sep 7, 2018 – May 21, 2019 · Past |
All 12 people
| Person | Seat |
|---|---|
| Charles Conway | Chief Scientific Officer · May 3, 2017 – Oct 3, 2022 · Past |
| James Engelhart | Strategic Advisor · May 3, 2017 – Oct 3, 2022 · Past |
Log in to ask 6ix AI your own questions about Biohaven Pharmaceutical Holding Co Ltd.